MYL - Mylan N.V.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
38.29
-0.02 (-0.05%)
As of 9:30AM EDT. Market open.
Stock chart is not supported by your current browser
Previous close38.31
Open38.29
Bid36.30 x 1000
Ask38.72 x 2900
Day's range38.19 - 38.29
52-week range29.39 - 47.82
Volume29,696
Avg. volume4,567,896
Market cap19.737B
Beta1.32
PE ratio (TTM)28.28
EPS (TTM)1.35
Earnings date7 Aug 2018 - 13 Aug 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend date2007-06-27
1y target est49.05
Trade prices are not sourced from all markets
  • Dr. Reddy's/Mylan Get FDA Nod for First Generic of Suboxone
    Zacks10 days ago

    Dr. Reddy's/Mylan Get FDA Nod for First Generic of Suboxone

    Dr. Reddy's (RDY) and Mylan announced that the FDA approved the first generic version of Suboxone (Buprenorphine and Naloxone Sublingual Film) under-the-tongue film for the treatment of opioid addiction.

  • Company News For Jun 15, 2018
    Zacks10 days ago

    Company News For Jun 15, 2018

    Companies In The News are: ETSY,RCL,MYL,GSK,TWTR

  • Reuters - UK Focus10 days ago

    UK's Indivior to seek injunction after rival gets FDA approval for generics

    Britain's Indivior (Frankfurt: 2IVA.F - news) said on Friday it would pursue all legal remedies, including seeking an immediate injunction against the U.S Food and Drug Administration's (FDA) decision to approve the first generic versions of Suboxone Film, an opioid addiction treatment. Indivior, which was spun out from Reckitt Benckiser (Xetra: A0M1W6 - news) in 2014, stuck to its 2018 guidance saying that until the details of Dr. Reddy's market entry of the drug's generic version is confirmed.

  • Reuters - UK Focus10 days ago

    Indivior shares dive after Dr Reddy's gets FDA approval for generic

    Britain's Indivior (Frankfurt: 2IVA.F - news) fell by more than 20 percent on Friday after the U.S Food and Drug Administration (FDA) approved the first generic versions of Suboxone Film, an opioid addiction treatment that generates 80 percent of its revenue. Shares (Berlin: DI6.BE - news) in Indivior, which was spun out from Reckitt Benckiser in 2014, were down 22.7 percent at 0925 GMT and the biggest loser on the FTSE midcap index. India's Dr Reddy's Laboratories received FDA approval for a copy-cat version of the treatment, which has been rapidly losing market share due to competition from generics.

  • Associated Press11 days ago

    FDA clears 1st generic film strip of addiction drug Suboxone

    U.S. regulators have approved the first generic version of an under-the-tongue film for treating opioid addiction.

  • Barrons.com11 days ago

    After the Bell: Dow Dips 26 Points, Nasdaq Hits New High as Market Tries to Make Up Its Mind

    The Dow Jones Industrial Average finished lower today, but the other major indexes fared better. •...and explain why Twitter (TWTR) soared. The S&P 500 has come to a standstill, but don't expect it to stay that way for long.

  • MarketWatch11 days ago

    FDA approves generic version of Suboxone film

    The U.S. Food and Drug Administration late Thursday said it approved the first generic version of a Suboxone under-the-tongue film for the treatment of opioid addiction. Mylan Technologies Inc., a subsidiary ...

  • Why Oracle, Mylan, and Tailored Brands Slumped Today
    Motley Fool11 days ago

    Why Oracle, Mylan, and Tailored Brands Slumped Today

    Find out why one of these stocks fell more than the others.

  • Mylan (MYL) to Get CRL Again for Generic Advair from FDA
    Zacks11 days ago

    Mylan (MYL) to Get CRL Again for Generic Advair from FDA

    Mylan (MYL) suffers another setback with its ANDA for Advair as the FDA refuses to approve the same, due to minor deficiencies.

  • FDA Rejects Mylan’s Generic Advair Again, Stock Falls
    Market Realist11 days ago

    FDA Rejects Mylan’s Generic Advair Again, Stock Falls

    On June 13, Mylan (MYL) announced that the FDA didn’t approve its generic version of GlaxoSmithKline’s (GSK) Advair Diskus, an asthma drug and inhaler combination. The FDA cited “minor deficiencies” in Mylan’s ANDA (abbreviated new drug application) for its generic Advair, which was first dismissed by the FDA in March 2017.

  • Investors Should Cut Mylan 'Some Slack' On Delayed Generic — But Haven't
    Investor's Business Daily11 days ago

    Investors Should Cut Mylan 'Some Slack' On Delayed Generic — But Haven't

    Investors didn't cut Mylan any slack Thursday after the company announced U.S. regulators would likely delay its generic version of blockbuster asthma inhaler Advair.

  • General Electric dips, Microsoft up slightly, Mylan under pressure
    Yahoo Finance11 days ago

    General Electric dips, Microsoft up slightly, Mylan under pressure

    Let’s check out the Yahoo Finance charts of the day.

  • Tesla, Microsoft, Apple Rise in Pre-Market, Mylan Slumps
    Investing.com11 days ago

    Tesla, Microsoft, Apple Rise in Pre-Market, Mylan Slumps

    Investing.com - Stocks in focus in pre-market trade Thursday:

  • Reuters - UK Focus11 days ago

    BUZZ-Mylan: Out of breath as delay feared for generic Advair

    ** Shares of Mylan NV down 4.4 pct to $39.83 in Thurs trading ** Co late on Wed said U.S. health regulators were unable to approve its generic version of GlaxoSmithKline's blockbuster inhaled lung drug ...

  • Stocks Start Higher On ECB Outlook: Etsy, 2 IPOs Seize New Highs
    Investor's Business Daily11 days ago

    Stocks Start Higher On ECB Outlook: Etsy, 2 IPOs Seize New Highs

    Mylan and Oracle dragged on early trade, but positive news out of Europe sent futures higher, and IPOs Etsy, Huya and Pivotal were poised to nail news highs.

  • Mylan Tumbles On Likely Delay For Its Copycat Of Blockbuster Inhaler
    Investor's Business Daily12 days ago

    Mylan Tumbles On Likely Delay For Its Copycat Of Blockbuster Inhaler

    Mylan shares plunged late Wednesday after the FDA identified "minor deficiencies" in its application for a generic copy of GlaxoSmithKline's drug Advair.

  • FDA finds deficiencies in Mylan's generic Advair
    Business Insider UK12 days ago

    FDA finds deficiencies in Mylan's generic Advair

    Thomson Reuters(Reuters) - U.S. drugmaker Mylan NV said on Wednesday that U.S. health regulators could not approve its generic version of GlaxoSmithKline's blockbuster inhaled lung drug, Advair, and cited "minor deficiencies" with the copycat version.

  • FDA finds deficiencies in Mylan's generic Advair
    Business Insider UK12 days ago

    FDA finds deficiencies in Mylan's generic Advair

    Thomson Reuters

  • Valeant Pharmaceuticals’ Valuation on June 8
    Market Realist14 days ago

    Valeant Pharmaceuticals’ Valuation on June 8

    As we discussed earlier, Valeant Pharmaceuticals (VRX) reported a non-GAAP EPS of $0.88 on revenues of ~$2.0 billion during the first quarter. Valeant had a 5.4% decline in its year-over-year revenues during the first quarter due to a 9% decrease in operating revenues. The decrease was partially offset by the favorable impact of foreign exchange—compared to revenues of ~$2.1 billion during the first quarter of 2017.

  • Mylan (MYL) Up 10.2% Since Earnings Report: Can It Continue?
    Zacks17 days ago

    Mylan (MYL) Up 10.2% Since Earnings Report: Can It Continue?

    Mylan (MYL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Company News For Jun 6, 2018
    Zacks19 days ago

    Company News For Jun 6, 2018

    Companies in the news are: PANW,SBUX,MYL,HDS

  • MarketWatch19 days ago

    Mylan shares zoom on key approval and $4.5 billion market opportunity

    Being first to market helps Mylan, as does the competitive landscape for Neulasta biosimilarsBloomberg NewsHeather Bresch, chief executive officer of Mylan, speaks during an interview in New York in 2016. Mylan NV marked a major success late Monday with the first U.S. approval of a biosimilar version of Neulasta, an anti-infective used for patients undergoing cancer treatment. Biosimilar drugs are copycat versions of expensive biologic drugs, which treat complex diseases like cancer, multiple sclerosis and diabetes.

  • Mylan (MYL) Gets FDA Approval for Biosimilar of Neulasta
    Zacks20 days ago

    Mylan (MYL) Gets FDA Approval for Biosimilar of Neulasta

    Mylan (MYL) and partner Biocon get a significant boost with the FDA approval for Fulphila, a biosimilar of Amgen's Neulasta.

  • Mylan Spikes After FDA Approves Its Knockoff Of Amgen's Drug
    Investor's Business Daily20 days ago

    Mylan Spikes After FDA Approves Its Knockoff Of Amgen's Drug

    Mylan spiked to a nearly eight-week high Tuesday after the FDA approved its copycat drug to Amgen's blockbuster medication Neulasta, a treatment that is used to stimulate bone marrow.

  • Associated Press20 days ago

    Mylan and Twitter rise while Starbucks and Genesco slump

    Stocks that moved substantially or traded heavily Tuesday: Starbucks Corp., down $1.39 to $55.68 Howard Schultz is stepping down as the coffee chain's executive chairman. G-III Apparel Group Ltd., up $4.65 ...

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes